Zydus Lifesciences gets USFDA approval for generic acne treatment gel

Zydus Lifesciences Ltd received final approval from the US Food and Drug Administration (USFDA) to market its generic version of Dapsone gel 7.5% for acne treatment. The gel is manufactured at their facility in Ahmedabad. Dapsone gel 7.5% had annual sales of $35.8 million in the US, according to IQVIA MAT March 2024 data, as reported in a regulatory filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ytp4Aw6
via IFTTT